Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome
Top Cited Papers
Open Access
- 26 March 2009
- journal article
- Published by American Society of Hematology in Blood
- Vol. 113 (13) , 3088-3091
- https://doi.org/10.1182/blood-2008-09-179895
Abstract
Mutations in CCAAT/enhancer binding protein α (CEBPA) are seen in 5% to 14% of acute myeloid leukemia (AML) and have been associated with a favorableKeywords
This publication has 20 references indexed in Scilit:
- Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic CellsClinical Cancer Research, 2005
- CEBPA point mutations in hematological malignanciesLeukemia, 2005
- C/EBPα mutations in acute myeloid leukaemiasNature Reviews Cancer, 2004
- Prognostically Useful Gene-Expression Profiles in Acute Myeloid LeukemiaNew England Journal of Medicine, 2004
- CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating MutationsJournal of Clinical Oncology, 2004
- Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2Genes, Chromosomes and Cancer, 2003
- Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AMLThe Hematology Journal, 2003
- Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)Blood, 2002
- Diagnosis of multiple cancer types by shrunken centroids of gene expressionProceedings of the National Academy of Sciences, 2002
- Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemiaNature Genetics, 2001